mitomycin-c kyowa 2 mg, powder for solution for in 2 milligram pdr for soln for injection
kyowa hakko kirin uk ltd - mitomycin - pdr for soln for injection - 2 milligram
mitomycin-c kyowa 20 mg, powder for solution for i 20 milligram pdr for soln for injection
kyowa hakko kirin uk ltd - mitomycin - pdr for soln for injection - 20 milligram
imatinib siegfried 100mg film-coated tablets
kohne pharma gmbh - imatinib 100 mg - film-coated tablet
imatinib siegfried 400mg film-coated tablets
kohne pharma gmbh - imatinib 400 mg - film-coated tablet
imatinib fair med
fair-med healthcare gmbh planckstr. 13, 22765 hamburg, germany - imatinib - film-coated tablet - imatinib 100 mg - antineoplastic agents
imatinib fair med
fair-med healthcare gmbh planckstr. 13, 22765 hamburg, germany - imatinib - film-coated tablet - imatinib 400 mg - antineoplastic agents
imatinib bioorganics 100mg
bioorganics bv microweg 22, 6545cm nijmegen, netherlands - imatinib - film-coated tablet - imatinib 100 mg - antineoplastic agents
imatinib bioorganics 400mg
bioorganics bv microweg 22, 6545cm nijmegen, netherlands - imatinib - film-coated tablet - imatinib 400 mg - antineoplastic agents
imatinib 100 milligram capsules hard
cipla (eu) limited - imatinib mesilate - capsules hard - 100 milligram - other cytostatics - antineoplastic agents; protein kinase inhibitor - it s indicated for the treatment of: paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid; leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated; phase or blast crisis.; adult patients with ph+ cml in blast crisis.; adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy; adult patients with relapsed or refractory ph+ all as monotherapy; adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived; growth factor receptor (pdgfr) gene re-arrangements.; adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement
imatinib 400 milligram capsules hard
cipla (eu) limited - imatinib mesilate - capsules hard - 400 milligram - other cytostatics - antineoplastic agents; protein kinase inhibitor - it is indicated for the treatment of: paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid; leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment; paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated; phase or blast crisis; adult patients with ph+ cml in blast crisis; adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy; adult patients with relapsed or refractory ph+ all as monotherapy; adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived; growth factor receptor (pdgfr) gene re-arrangements; adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement